

Cite this: *RSC Adv.*, 2018, 8, 37623

# Synthesis of novel cyclodextrin-modified reduced graphene oxide composites by a simple hydrothermal method†

Qingli Huang,<sup>ab</sup> MingYan Li,<sup>a</sup> LiLi Wang,<sup>b</sup> Honghua Yuan,<sup>b</sup> Meng Wang,<sup>b</sup>  
Yongping Wu<sup>ID</sup>\*<sup>a</sup> and Ting Li<sup>\*b</sup>

Cyclodextrin ( $\beta$ -CD)-functionalized reduced graphene oxide was successfully synthesized by a simple hydrothermal method, followed by conjugating with polyethylene glycol (PEG) and folic acid (FA). Microscopic and spectroscopic techniques were used to characterize the nanocomposites. Photothermal experiments showed that  $\beta$ -CD-functionalized reduced graphene oxide exhibited higher photothermal conversion efficiency in the near infrared region than reduced graphene oxide functionalized with other molecules under the same conditions. Cytotoxicity experiments indicated that rGO@CD@PEG@FA possessed good biocompatibility even at high concentration. When doxorubicin (DOX) was loaded on the rGO@CD@PEG@FA nanocomposite, it showed the stimulative effect of heat, pH response, and sustained drug release. Cytotoxicity experiments also confirmed the targeted effect and high efficiency of the combined therapy. The findings of the present study provide an ideal drug delivery system for malignant cancer therapy due to the advanced synergistic chemo-photothermal targeted therapy and good drug release properties.

Received 20th September 2018

Accepted 19th October 2018

DOI: 10.1039/c8ra07807f

rsc.li/rsc-advances

## 1. Introduction

Ovarian cancer is one of the leading causes of cancer death in women worldwide. Despite advances in medicine, many women with ovarian cancer continue to die of this malignancy. Chemotherapy is an important clinical therapeutic modality for ovarian cancers, with the introduction of various antitumor drugs such as doxorubicin (DOX).<sup>1,2</sup> However, the low therapeutic efficacy and serious side effects limit its further applications of DOX. To overcome these problems, drug delivery systems have been designed by many groups.<sup>3–10</sup> A wide variety of nanoparticles (NPs), including inorganic oxide,<sup>3,4</sup> graphene,<sup>5–7</sup> carbon nanotubes<sup>8</sup> and noble metal nanoparticles,<sup>9,10</sup> have been employed. Among these nanoparticles, graphene oxide (GO) and reduced graphene oxide (rGO) have been widely used in drug delivery systems.<sup>5–7,11–15</sup>

However, delivery systems using bare nanoparticles often suffer from many disadvantages, including burst drug release, lack of protection from enzymatic degradation, and low stability in aqueous media, which limit their further application. Recently, polymers have been designed to modify graphene

oxide (GO) and reduced graphene oxide (rGO) and render new physicochemical and biological advantages to the bare GO or rGO.<sup>16–19</sup> Cyclodextrins (CDs), as biodegradable polymers, could modify the NPs' behavior at the biointerfaces and improve control over drug release.<sup>20–23</sup> There are several advantages: (i) CD itself has good ability to load drugs; (ii) CDs can work as capping molecules to cover the GO carriers and protect the loaded compounds from the external environment; (iii) CDs have good biocompatibility, facilitating the safe and efficient delivery of drugs; and (iv) CDs have many active groups, which could be modified further by other molecules. Owing to these advantages, CDs have been reported for the delivery of several therapeutics.<sup>24–27</sup>

As a traditional therapy method, chemotherapy sometimes does not achieve the ideal therapeutic effect. Photothermal therapy (PTT), as a minimally invasive therapeutic methodology, has attracted much attention as a promising supplement to traditional chemotherapy.<sup>28</sup> The development of the near-infrared (NIR) laser-induced PTT depends on gaining access to biocompatible and efficient photothermal coupling agents. As well-known NIR photothermal conversion agents, GO and rGO have been widely investigated due to their strong light-absorbing capability and encouraging photothermal therapeutic effects in both *in vitro* and *in vivo* experiments.<sup>28–37</sup> Though some progress has been achieved, the development of methods to synthesize GO (rGO)-based therapeutic systems is necessary. In addition, during cancer therapy, suitable targeting of tumor cells is very important because non-specific targeting

<sup>a</sup>Department of Pathology, Laboratory of Clinical and Experimental Pathology, Xuzhou Medical University, No. 209 Tongshan Road, Xuzhou, Jiangsu, 221004, China

<sup>b</sup>Research Facility Center for Morphology of Xuzhou Medical University, No. 209 Tongshan Road, Xuzhou, Jiangsu, 221004, China

† Electronic supplementary information (ESI) available. See DOI: 10.1039/c8ra07807f

can lead to destruction of normal cells. Lack of suitable targeting to tumor cells seriously confines rGO's therapeutic applications. For ovarian cancer, the folate receptors are over-expressed on the surface of the cancer cells. Folic acid (FA) molecules could thus be used to target these cells.<sup>38–43</sup>

Herein, we report the rational design and successful synthesis of rGO@CD@PEG@FA nanocomposites by a simple hydrothermal method. The as-prepared rGO@CD@PEG@FA nanocomposites show low cytotoxicity and excellent photothermal conversion *in vitro*, which is promising for photothermal therapy (PPT) against cancer. When the anticancer drug doxorubicin (DOX) is loaded into rGO@CD@PEG@FA nanocomposites, it is effectively delivered to target ovarian cancer cells with a pH-sensitive release profile and thus employed for chemotherapy of cancer cells. Importantly, the combination of PPT and chemotherapy demonstrates better therapy effects on cancer cells than the individual therapy approaches *in vitro*.

## 2. Experimental section

### 2.1. Material

Graphene oxide (GO) was obtained from XFNANO Co., Ltd. (Nanjing, China). Doxorubicin hydrochloride (DOX), (3-aminopropyl)triethoxysilane (APTES), carbodiimide (EDC), *N*-hydroxysuccinimide (NHS) and folic acid (FA) were purchased from Aladdin Reagent Co., Ltd. (Shanghai, China). 6-Amino-6-deoxy- $\beta$ -cyclodextrin (CD) was acquired from Zhiyuan Biotechnology Co., Ltd. (Binzhou, China). Dulbecco's modified Eagle medium (DMEM), penicillin-streptomycin, and fetal calf serum (FBS) were purchased from Kaiji Biotechnology Co., Ltd. (Nanjing, China). Cell counting kit-8 (CCK-8) was purchased from VICMED Biotechnology Co., Ltd. (Xuzhou, China). Carboxymethyl-PEG-carboxymethyl (MW 10 000) was obtained from Yare Biotechnology Co., Ltd. (Shanghai, China). All chemicals are analytically pure and were used as received without further purification. Deionized water was used throughout the experiment.

### 2.2. Methods

**2.2.1 Synthesis of the rGO@CD.** 100 mg of 6-amino-6-deoxy- $\beta$ -cyclodextrin (CD) was added to the GO suspension with 24 mL water (1 mg mL<sup>-1</sup>), respectively, and stirred continuously for 1 h at room temperature. Then, the mixed solution was transferred into a Teflon-lined autoclave of 30 mL capacity. After being sealed and heated at 100 °C for 12 h, the autoclave was cooled to room temperature naturally. The resulting products were collected by centrifugation, washed with distilled water and ethanol several times, and finally dried. rGO modified by different molecules [1 mL (3-aminopropyl)triethoxysilane (APTES) and 100 mg albumin from bovine serum (BSA)] were also prepared using the same procedure.

### 2.2.2 Synthesis of the rGO@CD@PEG

10 mg rGO@CD was dispersed in 10 mL deionized water by ultrasonication. Then, 20 mg carboxymethyl-PEG-

carboxymethyl was added into the above solution and stirred at room temperature for 12 h. The resulting products were collected by centrifugation, washed with distilled water and ethanol, and finally stored in 10 mL deionized water.

### 2.2.3 Preparation of the rGO@CD@PEG@FA

Briefly, 13 mg folic acid was dispersed in 12 mL PBS solution by simple ultrasonication. Then, 30 mg of 1-ethyl-3-(3-(dimethylamino)propyl)-carbodiimide (EDC) and 50 mg of *N*-hydroxysuccinimide (NHS) were added into the solution, and the reaction mixture was allowed to stir for 6 h in the dark. Thus, the activated folic acid solution was obtained. Finally, 8 mL rGO@CD@PEG solution was added dropwise to 4 mL activated folic acid solution. The reaction mixture was allowed to stir overnight in the dark. Further dialysis was carried out using molecular weight cut-off membrane (3500 Da, MWCO) to remove unreacted molecules (<3000 MW) such as NHS, EDC and unreacted FA.

### 2.2.4 DOX loading and release

5 mL DOX solution (2 mg mL<sup>-1</sup>) was added to 5 mL of the as-prepared rGO@CD@PEG@FA solution (2 mg mL<sup>-1</sup>) under vigorous stirring for 12 h in the dark. Unbound DOX particles were removed by ultracentrifugation at 12 000 rpm. The unloaded DOX concentration and DOX loading amount were calculated from a calibration curve of several DOX solutions with known concentrations using a Mode 680 Microplate Reader (BIO-RAD, USA). The release of DOX was tested in phosphate-buffered solution with different pH levels at 37 °C. The mixture was centrifuged a certain number of times to measure the absorbance of the supernatant and estimate the released amount. For NIR laser irradiation, the samples were irradiated by 808nm laser (2 W, LWIRL808-10W-F) for 10 min at a certain time interval.

### 2.3. Characterization

TEM images of the as-prepared samples were obtained by a transmission electron microscopy (FEI Tecnai 12). FTIR spectra were recorded in the transmittance mode in the range of 400–4000 cm<sup>-1</sup> at using a Cary 610/670 spectrometer (Varian, USA). The as-prepared samples were thoroughly milled with KBr into a pellet before the measurement. UV-vis absorption spectra were recorded on a Shimadzu UV-2550 spectrophotometer in the range of 200–800 cm<sup>-1</sup>. The Raman spectra were obtained on a Renishaw Invia Raman spectrometer using 532 nm laser at room temperature in the range of 2000–400 cm<sup>-1</sup>. An 808 nm laser (LWIRL808-10W-F, Laserwave Co.) was utilized as a selected NIR light to irradiate rGO with different aqueous dispersions of modifying molecules (3 mL, 100  $\mu$ g mL<sup>-1</sup>) to induce photothermal effect. Cytotoxicity assays were conducted on a microplate reader (Bio-rad, USA) according to a standard CCK-8 method. The relative cell viability was measured by comparison with the control well containing only the cells.



## 2.4. Cell culture and viability assay

**2.4.1 Cell culture.** Ovarian cancer cells (SKOV3) were cultured in Dulbecco's modified Eagle medium (DMEM) supplemented with 10% FBS and 1% (v/v) penicillin–streptomycin. Cells were incubated for 3 days in a humidified 5% CO<sub>2</sub> containing balanced air at 37 °C. The media were changed every day.

**2.4.2 Cell viability assay.** Cytotoxicity assays were conducted according to a standard CCK-8 method. 200  $\mu$ L of the cultured cells, at a density of  $2 \times 10^4$  cells per mL, was placed in each well of a 96-well plate. Then, the cells were incubated at 37 °C in 5% CO<sub>2</sub> atmosphere for 24 h. The medium was removed, and cells were then treated with the medium containing as-prepared samples for 24 h at 37 °C in an atmosphere of 5% CO<sub>2</sub>. Finally, 10  $\mu$ L of CCK-8 was added into each well, and all cells were incubated for another 2 h. The absorbance of the solution at 450 nm was measured using a microplate reader. The relative cell viability was measured by comparing the control well containing only the cells.

## 3. Results and discussion

The morphology of the as-prepared samples is revealed by the transmission electron microscope (TEM) images in Fig. 1. It can be found that GO is relatively transparent, and its surface is smooth in Fig. 1a. After it was functionalized with CD (Fig. 1b), the product became rougher and thicker than GO, which reflects that the CD was grafted successfully on the surface of GO. For rGO@CD@PEG and rGO@CD@PEG@FA, it is difficult to observe an obvious change in morphology due to the influence of CD on the surface of rGO. The TEM images of rGO@CD@PEG@FA in PBS at pH 5.0 and 7.4 after 6 days are shown in Fig. S1.† No significant morphology and size changes were observed, indicating that rGO@CD@PEG@FA possesses good stability.

FTIR was also carried out to investigate the formation of rGO@CD@PEG@FA. For the pure GO spectrum in Fig. 2a, the characteristic peaks of GO at 3529, 1735, and 1090 cm<sup>-1</sup> are ascribed to the stretching vibrations of O–H, C=O and C–O in the carbonyl and carboxylic groups, respectively.<sup>44</sup> However, in the spectrum of rGO@CD (Fig. 2b), the characteristic absorption bands of oxygen-containing groups decreased dramatically,




Fig. 2 FTIR spectra of the prepared samples: (a) GO, (b) rGO@CD, (c) rGO@CD@PEG, (d) rGO@CD@PEG@FA.

indicating that GO has been reduced to rGO. A new peak at 1578 cm<sup>-1</sup> was found, which can be attributed to the N–H stretching vibration of 6-amino-6-deoxy-beta-cyclodextrin (CD).<sup>45</sup> With the appearance of the strong vibrations of methylene groups of PEG chains at 2921 cm<sup>-1</sup> in Fig. 2c, it is clearly demonstrated that PEG had been conjugated on the rGO@CD successfully.<sup>46</sup> In Fig. 2d, a broad peak from 3000–3500 cm<sup>-1</sup> (–COOH and –NH<sub>2</sub>) appeared, indicating the existing of FA on the composites.

UV-vis spectroscopic analysis was also used to ascertain the modification process of rGO. As shown in Fig. 3, a typical peak found at 230 nm corresponds to the  $\pi$ – $\pi^*$  transitions of the aromatic C=C bonds, and a weak shoulder peak at 300 nm is due to  $n$ – $\pi^*$  transitions of C=O bonds.<sup>47</sup> After modification and reduction by CD, a broad peak showed up around 266 nm, suggesting the reduction and modification of GO by CD.<sup>47</sup> However, there is little change in the absorption spectrum of rGO@CD@PEG due to no obvious absorption of PEG. For GO@CD@PEG@FA, a strong characteristic peak for folic acid at 282 nm appeared after grafting FA.<sup>48</sup>

Raman spectroscopy was also used to characterize the structure of GO in Fig. 4. The Raman spectrum has two prominent peaks at 1598 cm<sup>-1</sup> and 1350 cm<sup>-1</sup> corresponding to the well documented G and D bands. The G band is assigned to the stretching vibration of sp<sup>2</sup>-bonded carbon atoms, and the D band corresponds to the vibrations of carbon atoms with the sp<sup>3</sup> electronic configuration of disordered graphene.<sup>49</sup> After




Fig. 1 TEM images of (a) GO and (b) rGO@CD.




Fig. 3 UV-vis spectra of the prepared samples.






Fig. 4 Raman spectra of the prepared samples.




Fig. 5 Zeta potential of the prepared samples.

functionalizing with CD, the intensity ratio of the D and G bands of the product obviously increased in comparison with those of the original graphene oxide in the same test conditions, indicating the reduction of GO by CD.<sup>50</sup>

Moreover, the zeta potential of the obtained samples after each of the coating steps was also measured to monitor and verify the successful modification of  $\beta$ -CD, PEG and FA. As could be observed in Fig. 5, the zeta potential of GO was negative. After modification with  $\beta$ -CD, the composites showed positive zeta potential. Upon further modification with PEG and FA, there is an obvious change in zeta potential, indicating the composition change on the surface of rGO.

Graphene and graphene composites have good photothermal conversion performance and could be used as photothermal agents for treating cancer under NIR irradiation. The photothermal performance of the as-prepared samples was investigated in their aqueous dispersion ( $100 \mu\text{g mL}^{-1}$ ). Each sample was exposed to the same NIR irradiation (808 nm, continuous wave, 1 W, 300 s), and the temperature change was recorded using a temperature controller, model CH702. The rGO@CD showed excellent photothermal performance due to the modification of CD. In Fig. 6a, we can find that the temperature difference of the rGO@CD aqueous dispersion (about  $18^\circ\text{C}$ ) is larger than that of GO aqueous dispersion (about  $10^\circ\text{C}$ ) and deionized water (about  $4^\circ\text{C}$ ) with NIR irradiation for 300 s. It is obvious that an incremental amount of photothermal conversion effect was achieved when CD was modified on the surface of GO. To confirm the effect of CD, the photothermal performance of rGO functionalized with other




Fig. 6 The photothermal performance of samples under the same NIR irradiation condition (808 nm, continuous wave, 1 W, 300 s): (a) pure water, GO and rGO@CD; (b) rGO functionalized with different molecules (CD, APTES and BSA); (c) the products prepared with different amounts of CD; (d) the rGO@CD further modified with PEG and FA.

molecules (APTES and BSA) was also investigated under the same conditions. Fig. 6b shows the temperature difference of these molecules after NIR irradiation under the same conditions. It can be found that the rGO@CD had the best





photothermal efficiency among all samples. This may be due to the differences in the structure of CD, APTES and BSA. The better photothermal performance of the rGO@CD than the rGO-APTES and rGO-BSA can be assigned to the unique structure of CD, with its cavity structure.<sup>51,52</sup> The detailed mechanism needs further investigation. The photothermal conversion efficiency of rGO@CD was also calculated to be 46% according to previous literature<sup>53–55</sup> (Fig. S2–S4 in ESI†). In addition, the amount of CD on the surface of rGO also determined its photothermal performance. Fig. 6c shows the photothermal performance of rGO@CD with different amounts of CD (20 mg, 50 mg and 100 mg) after NIR irradiation under the same condition. The results showed that more CD contributed higher photothermal performance, which further accounts for the validity of CD. However, CD residue was found outside rGO when the amount of CD was larger than 100 mg. Herein, in our work, the appropriate amount of CD is 100 mg. At the same time, there is little influence on its photothermal performance when further modified with PEG and FA (Fig. 6d).

As a matter of fact, graphene and graphene composites are good candidates for loading and delivery of the anticancer drug DOX. Fluorescence spectra were used to ascertain the conjugation of DOX onto rGO@CD@PEG@FA@DOX. Fig. 7 represents the fluorescence spectra of all samples. Before DOX was loaded, no fluorescence signals were found for the samples (GO, rGO@CD, rGO@CD@PEG and rGO@CD@PEG@FA). However, after DOX was introduced, the appearance of the peak at 602 nm in rGO@CD@PEG@FA@DOX, which is characteristic for the pure DOX, confirmed the successful loading of DOX. The loading amount of DOX is  $0.91 \text{ mg mg}^{-1}$  at the neutral condition (pH 7.4) in our work. DOX has different prototropic forms at different pH values, owing to the presence of hydroxyl, carbonyl and amino groups on the sugar sidechain.<sup>56</sup> The primary amino groups of DOX molecules are mostly protonated when pH is 7.4.<sup>57</sup> As a hydrochloride salt, DOX can interact with  $\beta$ -CD in a 1 : 1 stoichiometry by hydrogen bonding and hydrophobic interactions in phosphate-buffered saline solution, resulting in an inclusion complex. The formation constant ( $K_f$ ) was reported to be  $210 \text{ M}^{-1}$  (25 °C).<sup>56</sup> In addition, the protonated form of DOX can also interact with the negative surface of GO by electrostatic interaction and hydrogen bonding.<sup>58</sup> Meanwhile, intracellular DOX release was also studied by cell fluorescence imaging (Fig. S5†). Red fluorescence was observed from DOX. Uniform bright red fluorescence in the SKOV3 cell could be observed, which was due to the release of fluorescent DOX entering the cell.

The release profile of DOX from rGO@CD@PEG@FA@DOX was studied at pH 7.4 (corresponding to the environment of blood) and 5.0 (simulating the pH in mature endosomes of tumor cells) at a temperature of 37 °C, respectively. As shown in Fig. 8 (labels a and b), the rate of drug release was predominantly in a pH-dependent manner, with a sustained profile. DOX was released continuously over 120 h, and 33.7% and 41.9% of total DOX was released at pH = 7.4 and 5.0, respectively. Noticeably, the drug release was rapid in the case of an acidic environment (tumor cell environment), which is consistent with early reports.<sup>17,39</sup> In addition, we found that the NIR




Fig. 7 Fluorescence spectra of the as-prepared samples.

laser irradiation could promote the release of DOX at pH = 5.0. About 52.2% of total DOX was released at pH = 5.0 under NIR laser irradiation, shown in Fig. 8(c). The cumulative heat destroys the electrostatic interaction between DOX and rGO, which significantly increases the release of DOX and the sensitivity of chemotherapy. As a result, rGO@CD@PEG@FA@DOX can be considered to be unique pH-sensitive and NIR-stimulated cancer therapeutic agent, which has potential to reduce the side effects and enhance the therapeutic effect.

DOX is used widely in chemotherapy for cancer. However, current chemotherapies have many well-known disadvantages, including systemic side effects, relatively poor specificity toward malignant tissues, drug resistance and low efficacy. It was previously demonstrated that photo-thermal therapy (PTT) could lead to precise targeted treatment at the specific site, which is considerably less invasive than surgery. GO and rGO can produce a large amount of active oxygen species (ROS) and could be used as PTT agents for cancer. Consequently, it was highly expected that the synthesized rGO@CD@PEG@FA@DOX possesses both chemotherapeutic and PTT properties. For cancer therapeutic agents, safety and *in vitro* cytocompatibility are essential. To show the safety and *in vitro* cytocompatibility of rGO@CD@PEG@FA, the ovarian cancer cells (SKOV3) were incubated for 24 h with different concentrations of the as-prepared samples ( $25 \mu\text{g mL}^{-1}$ ,  $50 \mu\text{g mL}^{-1}$  and  $100 \mu\text{g mL}^{-1}$ , see Fig. 9). Compared to viability of cells with pure GO, higher viability of cells was found when they were incubated with rGO@CD@PEG@FA (Fig. 9a). Fig. 9b shows the anticancer




Fig. 8 DOX release profile (a) at pH = 7.4, (b) without and (c) with laser irradiation at pH = 5.0 over 120 h.






Fig. 9 (a) Viability of SKOV3 cells incubated with different samples at different concentrations. (b) Viability of SKOV3 cells incubated with  $100 \mu\text{g mL}^{-1}$  rGO@CD@PEG@FA@DOX for 24 h without and with NIR laser irradiation at low power density ( $600 \text{ mW cm}^{-2}$  for 5 min).

performance of rGO@CD@PEG@FA@DOX by chemotherapy and synergistic chemo-photothermal therapy methods. There was almost no change for the pure medium group under NIR laser irradiation. The cell viability is lower with synergistic chemo-photothermal therapy (23%) than with single chemotherapy (36%). This means the 808 nm NIR effectively activated rGO@CD@PEG@FA@DOX and had a lethal effect on cancer cells. The as-prepared rGO@CD@PEG@FA@DOX is promising as a cancer therapeutic agent *via* synergistic chemo-photothermal therapy, and its possible mechanism is discussed.<sup>59–63</sup> On one hand, the intrinsic high optical absorption of rGO composites in the near-infrared (NIR) region elevated the temperature of tumor sites, generating many ROS such as  $\cdot\text{OH}$ ,  $\text{O}_2^{\cdot-}$  and  $\text{H}_2\text{O}_2$ . These  $\cdot\text{OH}$ ,  $\text{O}_2^{\cdot-}$  and  $\text{H}_2\text{O}_2$  can damage and/or inhibit proteins in several ways—one is the direct oxidation of amino acids by ROS. Thus, photothermal ablation of tumors occurred. On the other hand, the heat generated by photo-thermal effect could destroy the electrostatic interaction between DOX and GO composites, which significantly increases the release of DOX and the cells' sensitivity to chemotherapy. Furthermore, the photochemical internalization effect, which is related to site-specific release of chemotherapeutics inside the cells, led to disintegration of endosomes and lysosomes.

Different from the high expression level of folate receptor in ovarian cancer cells, the folate receptor expression level is very low in prostate cancer cells (DU145). Finally, the targeting ability of rGO@CD@PEG@FA@DOX for ovarian cancer cells was evaluated by the introduction of prostate cancer cells




Fig. 10 Viability of DU145 cells incubated without and with  $100 \mu\text{g mL}^{-1}$  rGO@CD@PEG@FA@DOX for 24 h.

(DU145) in Fig. 10. It can be seen that rGO@CD@PEG@FA@DOX exhibited significantly higher cytotoxicity in ovarian cancer cells (36% viability, Fig. 9) than that in prostate cancer cells (51% viability, Fig. 10). This could be due to the different expression level of folate receptor in different cells. The same phenomenon was observed in early works, which demonstrated that folate could significantly enhance the cellular uptake of the drug delivery system in cells with high expression levels of folate receptor.<sup>39–43</sup>

## 4. Conclusion

In summary, we have designed and synthesized a rGO@CD@PEG@FA nanocomposite as a new nanohybrid drug carrier and photothermal therapeutic agent. Various spectroscopic and microscopic techniques were used to characterize this nanocomposite. The results show that CD, PEG and FA were successfully conjugated on the surface of rGO. The as-prepared rGO@CD@PEG@FA nanocomposite not only showed good pH-triggered release of DOX but also had good targeting ability. Furthermore, this nanocomposite showed photo-thermal conversion properties under NIR irradiation. Based on the present findings, the rGO@CD@PEG@FA nanocomposite has the potential for tumor-targeted release of drugs and heat, facilitating targeted cancer chemo-photothermal therapy in a single system.

## Conflicts of interest

There are no conflicts to declare.

## Acknowledgements

This work is funded by the National Natural Science Foundation of China (No. 81372479 and 21505118), Natural Science Foundation of Jiangsu Province of China (BK 20150438) and Post-doctoral Research Funding Program of Jiangsu Province of China (1701133C).

## References

- 1 H. Ye, A. A. Karim and X. J. Loh, *Mater. Sci. Eng., C*, 2014, **45**, 609–619.



- 2 Z. Y. Xu, S. Wang, Y. J. Li, M. W. Wang, P. Shi and X. Y. Huang, *ACS Appl. Mater. Interfaces*, 2014, **6**, 17268–17276.
- 3 S. C. Mohanta, A. Saha and P. S. Devi, *Mater. Today*, 2018, **5**, 9715–9725.
- 4 N. Cristina, V. E. Sergio and d. P. C. Maria, *J. Biol. Inorg. Chem.*, 2018, **23**, 331–345.
- 5 R. Lima-Sousa, D. Melo-Diogo, C. G. Alves, E. C. Costa, P. Ferreira, R. O. Louro and I. J. Correia, *Carbohydr. Polym.*, 2018, **200**, 93–99.
- 6 D. P. Singh, C. E. Herrera, B. Singh, S. Singh, R. K. Singh and R. Kumar, *Mater. Sci. Eng., C*, 2018, **86**, 173–197.
- 7 M. Orecchioni, R. Cabizza, A. Bianco and L. G. Delogu, *Theranostics*, 2015, **5**, 710–723.
- 8 Z. Li, A. L. B. de Barros, D. C. F. Soares, S. N. Moss and L. Alisaraie, *Int. J. Pharm.*, 2017, **524**, 41–54.
- 9 S. Laksee, S. Puthong, P. Kongkavitoon, T. Palaga and N. Muangsinsin, *Carbohydr. Polym.*, 2018, **198**, 495–508.
- 10 G. Paramasivam, N. Kayambu, A. M. Rabel, A. K. Sundramoorthy and A. Sundaramurthy, *Acta Biomater.*, 2017, **49**, 45–65.
- 11 Y. Liu, H. Zhong, Y. Qin, Y. Zhang, X. F. Liu and T. Zhang, *RSC Adv.*, 2016, **6**, 30184–30193.
- 12 J. H. Zhu, M. J. Chen, Q. L. He, L. Shao, S. Y. Wei and Z. H. Guo, *RSC Adv.*, 2013, **3**, 22790–22824.
- 13 Y. Pan, N. G. Sahoo and L. Li, *Expert Opin. Drug Delivery*, 2012, **9**, 1365–1376.
- 14 S. Augustine, J. Singh, M. Srivastava, M. Sharma, A. Das and B. D. Malhotra, *Biomater. Sci.*, 2017, **5**, 901–952.
- 15 X. L. Wang and G. Q. Shi, *Phys. Chem. Chem. Phys.*, 2015, **17**, 28484–28504.
- 16 C. Wang, Z. Q. Zhang, B. B. Chen, L. Q. Gu, Y. Li and S. W. Yu, *J. Colloid Interface Sci.*, 2018, **516**, 332–341.
- 17 R. Wang, D. Shou, O. Lv, Y. Kong, L. H. Deng and J. Shen, *Int. J. Biol. Macromol.*, 2017, **103**, 248–253.
- 18 S. S. Mu, G. W. Li, Y. Y. Liang, T. Wu and D. Ma, *Mater. Sci. Eng., C*, 2017, **78**, 639–646.
- 19 Y. T. Fan, Q. Y. Sun, H. Gu, W. X. Li, Y. Y. Chen, J. Wang, N. L. Zhou and Y. H. Xiao, *Nanotechnology*, 2014, **25**, 255601.
- 20 N. Zafar, H. Fessi and A. Elaissari, *Int. J. Pharm.*, 2014, **461**, 351–366.
- 21 S. Bai, M. L. Hou, X. X. Shi, J. C. Chen, X. Q. Ma, Y.-E. Gao, Y. J. Wang, P. Xue, Y. J. Kang and Z. G. Xu, *Carbohydr. Polym.*, 2018, **193**, 153–162.
- 22 T. Loftsson, P. Jarho, M. Masson and T. Jarvinen, *Expert Opin. Drug Delivery*, 2005, **2**, 335–351.
- 23 S. Lu, A. Wang, Y. J. Ma, H. Y. Xuan, B. Zhao, X. D. Li, J. H. Zhou, L. Zhou and S. H. We, *Carbohydr. Polym.*, 2016, **148**, 236–242.
- 24 G. C. Wei, R. H. Dong, D. Wang, L. Feng, S. L. Dong, A. X. Song and J. C. Hao, *New J. Chem.*, 2014, **38**, 140–145.
- 25 E. Einafshar, A. H. Asl, A. H. Nia, M. Mohammadi, A. Malekzadeh and M. Ramezani, *Carbohydr. Polym.*, 2018, **194**, 103–110.
- 26 N. Meng, Y. T. Su, N. L. Zhou, M. Zhang, M. N. Shao, Y. T. Fan, H. M. Zhu, P. Yuan, C. Chi and Y. H. Xiao, *Int. J. Biol. Macromol.*, 2016, **93**, 117–122.
- 27 C. L. Wang, B. Li, W. F. Niu, S. S. Hong, B. Saif, S. B. Wang, C. Dong and S. M. Shuang, *RSC Adv.*, 2015, **5**, 89299–89308.
- 28 A. Saneja, R. Kumar, D. Arora, S. Kumar, A. K. Panda and S. Jaglan, *Drug Discovery Today*, 2018, **23**, 1115–1125.
- 29 M. Abdolahad, M. Janmaleki, S. Mohajerzadeh, O. Akhavan and S. Abbasi, *Mater. Sci. Eng., C*, 2013, **33**, 1498–1505.
- 30 Z. M. Markovic, L. M. Harhaji-Trajkovic, B. M. Todorovic-Markovic, D. P. Kepić, K. M. Arsin, S. P. Jovanović, A. C. Pantovic, M. D. Dramićanin and V. S. Trajkovic, *Biomaterials*, 2011, **32**, 1121–1129.
- 31 K. Yang, J. M. Wan, S. Zhang, B. Tian, Y. J. Zhang and Z. Liu, *Biomaterials*, 2012, **33**, 2206–2214.
- 32 H. Y. Liu, T. Li, Y. H. Liu, G. Q. Qin, X. P. Wang and T. S. Chen, *Nanoscale Res. Lett.*, 2016, **11**, 211.
- 33 W. Zhang, Z. Y. Guo, D. Q. Huang, Z. M. Liu, X. Guo and H. Q. Zhong, *Biomaterials*, 2011, **32**, 8555–8861.
- 34 B. Tian, C. Wang, S. Zhang, L. Z. Feng and Z. Liu, *ACS Nano*, 2011, **5**, 7000–7009.
- 35 A. Zuchowska, M. Chudy, A. Dybko and Z. Brzozka, *Sens. Actuators, B*, 2017, **243**, 152–165.
- 36 L. Zhou, L. Zhou, S. H. Wei, X. F. Ge, J. H. Zhou, H. J. Jiang, F. Y. Li and J. Shen, *J. Photochem. Photobiol., B*, 2014, **135**, 7–16.
- 37 Y.-W. Chen, Y.-L. Su, S.-H. Hu and S.-Y. Chen, *Adv. Drug Delivery Rev.*, 2016, **105**, 190–204.
- 38 L. Zhang, Y. C. Li and J. C. Yu, *J. Mater. Chem. B*, 2014, **2**, 452–470.
- 39 J. W. Tian, L. Ding, Q. B. Wang, Y. P. Hu, L. Jia, J.-S. Yu and H. X. Ju, *Anal. Chem.*, 2015, **87**, 3841–3848.
- 40 M. E. Mathew, J. C. Mohan, K. Manzoor, S. V. Nair, H. Tamur and R. Jayakumar, *Carbohydr. Polym.*, 2010, **80**, 442–448.
- 41 E. K. Park, S. B. Lee and Y. M. Lee, *Biomaterials*, 2005, **26**, 1053–1061.
- 42 X. B. Zhao and P. Liu, *RSC Adv.*, 2014, **4**, 24232–24239.
- 43 D. Depan, J. Shah and R. D. K. Misra, *Mater. Sci. Eng., C*, 2011, **31**, 1305–1312.
- 44 Q. L. Huang, J. M. Wang, W. X. Wei, Q. X. Yan, C. L. Wu and X. S. Zhu, *J. Hazard. Mater.*, 2015, **283**, 123–130.
- 45 A. Correia, M.-A. Shahbazi, E. Makilä, S. Almeida, J. Salonen, J. Hirvonen and H. A. Santos, *ACS Appl. Mater. Interfaces*, 2015, **7**, 23197–23204.
- 46 V. Georgiadou, G. Makris, D. Papagiannopoulou, G. Vourlias and C. Dendrinou-Samara, *ACS Appl. Mater. Interfaces*, 2016, **8**, 9345–9360.
- 47 D. Li, M. B. Müller, S. Gilje, R. B. Kaner and G. G. Wallace, *Nat. Nanotechnol.*, 2008, **3**, 101–105.
- 48 L. Zhan, Y. Zhang, Q. L. Zeng, Z. D. Liu and C. Z. Huang, *J. Colloid Interface Sci.*, 2014, **426**, 293–299.
- 49 H. Cao, X. Wu, G. Yin and J. H. Warner, *Inorg. Chem.*, 2012, **51**, 2954–2960.
- 50 S. Stankovich, D. A. Dikin, R. D. Piner, K. A. Kohlhaas, A. Kleinhammes, Y. Jia, Y. Wu, S. T. Nguyen and R. S. Ruoff, *Carbon*, 2007, **45**, 1558–1565.
- 51 J. M. Haider and Z. Pikramenou, *Chem. Soc. Rev.*, 2005, **34**, 120–132.
- 52 A. Kasprzak and M. Poplawska, *Chem. Commun.*, 2018, **54**, 8547–8562.



- 53 F. Wu, M. Zhang, H. W. Lu, D. Liang, Y. L. Huang, Y. H. Xia, Y. Q. Hu, S. Q. Hu, J. X. Wang, X. Y. Yi and J. Zhang, *ACS Appl. Mater. Interfaces*, 2018, **10**(26), 21939–21949.
- 54 M. Zhang, F. Wu, W. T. Wang, J. Shen, N. L. Zhou and C. Z. Wu, *Chem. Mater.*, DOI: 10.1021/acs.chemmater.8b00934.
- 55 M. Zhang, W. T. Wang, K. Graveran, N.-L. Zhou, J. Zhang and F. Wu, *Chem.–Eur. J.*, 2018, **24**, 12890–12901.
- 56 N. Husain, T. T. Ndou, A. M. de la Peña and I. M. Warnert, *Appl. Spectrosc.*, 1992, **46**, 652–658.
- 57 N. V. Roik and L. A. Belyakova, *Interface Focus*, 2016, **6**, 1–10.
- 58 K. Nawara, J. Romiszewski, K. Kijewska, J. Szczytko, A. Twardowski, M. Mazur and P. Krysinski, *J. Phys. Chem. C*, 2012, **116**, 5598–5609.
- 59 Y.-Y. Song, C. Li, X.-Q. Yang, J. An, K. Cheng, Y. Xuan, X.-M. Shi, M.-J. Gao, X.-L. Song, Y.-D. Zhao and W. Chen, *J. Mater. Chem. B*, 2018, **6**, 4808–4820.
- 60 D. Jaque, L. Martínez Maestro, B. del Rosal, P. Haro-Gonzalez, A. Benayas, J. L. Plaza, E. Martín Rodríguez and J. García Solé, *Nanoscale*, 2014, **6**, 9494–9530.
- 61 V. Shanmugam, S. Selvakumar and C.-S. Yeh, *Chem. Soc. Rev.*, 2014, **43**, 6254–6287.
- 62 T. Li, H. Y. Liu, G. N. Xi, Y. L. Pang, L. P. Wu, X. P. Wang and T. S. Chen, *J. Mater. Chem. B*, 2016, **4**, 2972–2983.
- 63 H. D. Chen, F. Y. Liu, Z. Lei, L. N. Ma and Z. X. Wang, *RSC Adv.*, 2015, **5**, 84980–84987.

